Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 3
1(100.0%)
1Total
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07229677Recruiting

Cohort Study of Arbovirus and Other Emerging Virus Infections in Fiji: AEVI-Fiji Cohort.

Role: collaborator

NCT03925480Phase 3Completed

Preventing Young Infant Infections Using Azithromycin in Labour (PreYIAL) Trial

Role: collaborator

NCT02276521Completed

Evaluation of Long Term Immunity Following HPV Vaccination

Role: collaborator

NCT02188862Completed

Genetic Susceptibility to Rheumatic Heart Disease in the Pacific Region

Role: collaborator

All 4 trials loaded